A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

PURPOSE: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotein, in patients with advanced cancers. MATERIALS AND METHODS: Patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, Hyun Jung, Heo, Dae-Seog, Cho, Joo-Youn, Han, Sae-Won, Chang, Hye-Jung, Yi, Hyeon-Gyu, Kim, Tae-Eun, Lee, Se-Hoon, Oh, Do-Youn, Im, Seock-Ah, Jang, In-Jin, Bang, Yung-Jue
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Cancer Association 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4132447/
https://ncbi.nlm.nih.gov/pubmed/25038758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2014.46.3.234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados